As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company's focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible for the growth of Novalung's sales activities.
Dr. Georg Matheis, who has been Managing Director of Novalung since its founding in 2003, commented: "I'm truly looking forward to working with Josef Bogenschütz, who brings with him extensive expertise in our core business, the development and manufacturing of artificial lungs."
Josef Bogenschütz worked together with Georg Matheis at the German company Jostra AG in the field of cardiac surgery before Jostra was sold to Maquet Cardiopulmonary AG eight years ago and Novalung GmbH was spun off as an independent company. During their time together they laid the foundation for the development of the iLA Membrane Ventilator, Novalung's flagship product for innovative ventilation therapy. "Since that time I have followed Novalung's development with great interest", Bogenschütz says. "Having built up and developed the Cardiopulmonary business at Maquet over the past several years, I am excited at the prospect of using my experience and focus to drive the development and positioning of Novalung as an innovative company in the field of ventilation." Bogenschütz explains his decision to move to Novalung after eight years at Maquet with his motto: "You have to have a vision for the future to be able to change the present."
Bogenschütz was most recently President and CEO at Maquet Cardiopulmonary AG. The 45-year-old mechanical engineer began his career in manufacturing management at Bizerba GmbH and Beru AG before entering the medical device field 11 years ago when he joined Jostra AG.
Dr. Georg Matheis, who has been Managing Director of Novalung since its founding in 2003, commented: "I'm truly looking forward to working with Josef Bogenschütz, who brings with him extensive expertise in our core business, the development and manufacturing of artificial lungs."
Josef Bogenschütz worked together with Georg Matheis at the German company Jostra AG in the field of cardiac surgery before Jostra was sold to Maquet Cardiopulmonary AG eight years ago and Novalung GmbH was spun off as an independent company. During their time together they laid the foundation for the development of the iLA Membrane Ventilator, Novalung's flagship product for innovative ventilation therapy. "Since that time I have followed Novalung's development with great interest", Bogenschütz says. "Having built up and developed the Cardiopulmonary business at Maquet over the past several years, I am excited at the prospect of using my experience and focus to drive the development and positioning of Novalung as an innovative company in the field of ventilation." Bogenschütz explains his decision to move to Novalung after eight years at Maquet with his motto: "You have to have a vision for the future to be able to change the present."
Bogenschütz was most recently President and CEO at Maquet Cardiopulmonary AG. The 45-year-old mechanical engineer began his career in manufacturing management at Bizerba GmbH and Beru AG before entering the medical device field 11 years ago when he joined Jostra AG.
